Potensi nanopartikel chitosan berbasis flavonoid fisetin dari buah stroberi (Fragaria x ananassa): modalitas terapi dalam penatalaksanaan TNBC

Felicia Puspita Sari, Kenny Satrio, I Gede Gita Sastrawan, I Gusti Ngurah Bagus Rai Mulya Hartawan


Breast cancer is ranked number one in the world as a cancer with the highest new cases reaching 1.7 million people (43.4%). Triple-Negative Breast Cancer (TNBC) has a worse prognosis than non-TNBC because of low 5-year survival rates and high recurrence rates. TNBC was also rated as more aggressive and invasive with high levels of nuclear mitotics. Currently, the use of natural food substances derived from fruits, vegetables, and spices is getting more attention because of its role as chemopreventive and chemotherapeutic agents, one of which is flavonoids. Fisetin (3,3',4',7-tetrahydroxyflavone) is a flavonol bioactive molecule found in fruits and vegetables such as apples and persimmons with the highest concentration found in strawberries (Fragaria x ananassa). One of the technologies being developed in the oncology field is nanoparticles. Nanoparticles are useful for delivering and releasing drugs to the target organs, as well as increasing the bioavailability of drugs so that drugs can work for a longer time. The combination of the flavonoid fisetin encapsulated with chitosan nanoparticles has the potential to become one of the therapeutic modalities in the management of TNBC.


TNBC, Fisetin, Chitosan, Proliferation, Apoptosis

Full Text:



Jiao Q, Wu A, Shao G, Peng H, Wang M, Ji S, Liu P, Zhang J. The latest progress in research on Triple Negative Breast Cancer (TNBC): Risk Factors, Possible Therapeutic Targets and Prognostic Markers. A Review of Triple Negative Breast Cancer. 2014; 6(9):1329-1335

Tao ZQ, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2015; 72:333338

Verma R, Lowen RL, Slater SE, Mihaimeed F, Jones JL. Pathological and Epidemiological Factors Associated with Advanced Stage at Diagnosis of Breast Cancer. British Medical Bulletin. 2012; 103:129-145

The Cancer Genome Atlas Network. Comprehensice Molecular Portraits of Human Breast Tumours. Nature. 2012. 490: 61-70

Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triplenegative Breast Cancer: Challenges and Opportunities of Heterogeneous Disease. Clinical Oncology. 2016; 13: 674-690

Foulkes WD, Smith IE, ReishFilho JS. Triple-negative Breast Cancer. The New England Journal of Medicine. 2010; 363:1938-1948

Reis-Filho JS, Tutt ANJ. Triple Negative Tumours: A Critical Review. Histopathology. 2008; 52:108-118

Ruijter CD, Veeck J, Hoon JPJ, Engeland M, Tjan-Heijnen VC. Characteristics of Triple-Negative Breast Cancer. Journal Cancer Res Clinical Oncology. 2011; 137: 183-192

American Cancer Society. Breast Cancer: Facts & Figures 20172018. Atlanta: American Cancer Society, Inc. 2017

O’Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ. The Fate of Chemoresistance in Triple Negative Breast Cancer (TNBC). BBA Clinical.2015;3:257-275

Khan N, Afaw F, Mukhtar H. Cancer Chemoprevention Through Dietary Antioxidants Progress and Promise. Antioxidants & Redox Signaling. 2008: 10(3): 475-510

Khan N, Syed DN, Ahmad N, Mukhtar H. Fisetin: A Dietary Antioxidant for Health Promotion. 2013; 19(2): 151-162

Cavalli R, Bisazza A, Trotta M, Argenziano M, Civra A. New chitosan nanobubbles for ultrasound- mediated gene delivery : preparation and in vitro characterization. 2012

Yang W, Peters JI, Williams RO. Inhaled nanoparticles — A current review. 2008;356:239–47

Liu X, Chem JM, Xue X, Liu X. Emerging functional nanomaterials for therapeutics. 2011;21(35).

Malorni L, Shetty PB, Angelis CD, Hilsenbeck S, RImawi MF, Elledge R, Osborne CK, Placido SD, Arpino G. Clinical and Biologic Features of TripleNegative Breast Cancers in A Large Cohort of Patients with Long-Term Follow-Up. Breast Cancer Res Treat. 2012;136(3):795-804

Bosch A, Eroles P, Zaragoza R, Vina JR, Lluch A. Triple-Negative Breast Cancer: Molecular Features, Pathogenesis, Treatment and Current Lines of Research. Cancer Treatment Reviews.2010;36:206-215

Kimira M, Arai Y, Shimoi K, and Watanabe S. Japanese intake of flavonoids and isoflavonoids from foods. J Epidemiol 8: 168–175, 1998

Y.S. Touil, N. Auzeil, F. Boulinguez, H. Saighi, A. Regazzetti, D. Scherman, et al., Fisetin disposition and metabolism in mice: identification of geraldol as an active metabolite, Biochem. Pharmacol. 82 (2011) 1731–1739

Smith ML, Murphy K, Doucette CD, Greenshields AL, Hoskin DW. The Dietary Flavonoid Fisetin Causes Cell Cycle Arrest, Caspase-Dependent Apoptosis, and Enhanced Cytotoxicity of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells. Journal of Cellular Biochemistry.2016; 117: 19131925

Syed DN, Adhami VM, Khan N, Khan MI, Mukhtar H. Exploring the Molecular Targets of Dietary Flavonoid Fisetin in Cancer. Seminars in Cancer Biology. 2016;40-41:130-140

Indran IR, Tufo G, Pervais S, Brenner C. Recent Advances in apoptosis, Mitochondria, and Drug Resistance in Cancer Cells. Biochimica et Biophysica Acta. 2011: 735-745

Elmore S. Apoptosis: A Review of Programmed Cell Death. Toxicol Pathol. 2007; 35(4):495-516

Prigent C, Dimitrov S. Phosphorylation of Serine 10 in Histone H3, What for?. Journal of Cell Science. 2013; 116: 36773685

Ham SL, Nasrollahi S, Shah KN,, Soltisz SP, Yun YH, Luker GD, Bishayee A, Tavana H. Phytochemicals potently inhibit migration of metastatic Breast Cancer Cells. Integrative Biology.2015;7(7):792-800